Generare, a French biotech startup, has recently secured €5 million in seed funding. This investment will bolster their ambitious project of discovering next-gen medicines within soil bacteria.
The funding, procured from notable investors like Teampact.ventures and VIVES Partners, is aimed at enhancing Generare’s technological capabilities. It will support the development of a ‘discovery factory,’ enabling the startup to industrialise its approach in the search for new bioactive molecules.
This innovative method extracts bioactive molecules, termed Natural Products (NPs), at an unparalleled speed, exploiting a decade’s worth of scientific research and advanced DNA sequencing techniques.
This multifaceted approach not only accelerates discovery but provides insights into potential ‘first-in-class’ therapeutic entities, delivering significant advancements in drug development.
The team’s expansive vision and scientific prowess position Generare as a leader in leveraging nature’s complexity to transform modern medicine.
Philippe Durieux of VIVES Partners emphasises Generare’s foundational expertise and pioneering research in utilising Nature’s chemical diversity, drawing parallels with historical breakthroughs like penicillin.
Their pioneering work in natural product discovery paves the way for future scientific breakthroughs, potentially changing the pharmaceutical landscape.
Generare’s endeavours signify a pivotal moment in biotechnology, promoting the efficient discovery of novel medicines through advanced genetic strategies.
Generare’s pioneering approach and recent funding have poised the company to redefine the realm of drug discovery. Their innovative methods unveil new, promising potentials within soil bacteria, setting a precedent for future biotech advancements.
